Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine plus Capecitabine

Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT01268384 - Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter